BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 28, 2016
View Archived Issues
Trial supports the use of sodium channel blocker phenytoin in acute optic neuritis
Read More
Pivotal phase III clinical trial of intravenous meloxicam begins at Recro Pharma
Read More
FDA accepts BLA for bezlotoxumab
Read More
Supinoxin demonstrates preclinical efficacy to treat renal cancer
Read More
Replikins selects peptide Zika virus vaccine for preclinical efficacy studies
Read More
Sumitomo Dainippon Pharma updates progress of third quarter of fiscal 2015
Read More
Blend Therapeutics secures Series C financing and changes name
Read More
Urine-exosome signature validated in prostate cancer patients
Read More
Roche Diagnostics and Lilly to develop Alzheimer's diagnostic
Read More
Stemedica completes enrollment in phase I/IIa study in stroke
Read More
MSI Methylation Sciences reports results from phase II trial of MSI-195 in MDD
Read More
Alpharmagen discloses nicotinic acetylcholine alpha7 modulators
Read More
University of Texas System patents mitochondrial GLS inhibitors
Read More
Serendex starts phase II trial of inhaled molgramostim in ARDS
Read More
BIND Therapeutics gives update on BIND-014 trials
Read More
ImmunoCellular Therapeutics enters research agreement with the University of Maryland
Read More
Aprecia Pharmaceuticals obtains financing to advance 3D-printed drug pipeline
Read More
Clovis begins phase Ib/II study of atezolizumab and rociletinib
Read More
Cyramza approved in Europe for NSCLC and colorectal cancer
Read More
First patient dosed in Zimura phase II/III trial
Read More
Breakthrough therapy designation for venetoclax for AML
Read More
Incyte to stop substudy within ruxolitinib phase II colorectal cancer study
Read More
